Emerging concepts in antihypertensive therapy: the benefits of angiotensin II blockade.
Essential hypertension affects more than 40 million Americans, or one in four adults. The prevalence of hypertension is greater among the African-American population, with a distressingly high rate of end-organ complications. Although diabetes mellitus has surpassed hyper tension as the dominant etiology of end-stage renal disease in the United States, kidney failure secondary to hypertensive nephrosclerosis remains a significant problem, particularly among African Americans. During the past decade, a shift in the paradigm for the renin-angiotensin system (RAS) has evolved from a circulating vasoactive cascade toward angiotensin II (ANG II) formation at the cellular level. The molecular components of the RAS have been identified in cells, documenting the existence of an autocrine tissue RAS, as well as the presence of enzymes, which catalyze the formation of ANG II by angiotensin-converting-enzyme-independent pathways, providing new targets for therapeutic intervention. The latter challenge has important clinical implications, in view of recent evidence implicating ANG II in pathologic cell growth and cell death and fundamental events in the remodeling of the vascular wall and myocardium in the setting of hypertension. This review focuses on ANG II as a major determinant of end-organ damage in essential hypertension; the benefits of ANG II blockade at the end-organ level, which appear to be independent of the blood pressure-lowering effect; and the emerging role for ANG II receptor antagonists as first-line agents in the treatment of essential hypertension.
Meggs
L G
LG
Department of Medicine, UMDNJ-New Jersey Medical School, Newark 07103, USA.
Kodali
P
P
D000328:Adult; D000804:Angiotensin II / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D017209:Apoptosis; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology*; D009206:Myocardium / Q000473:pathology; D011945:Receptors, Angiotensin; D012084:Renin-Angiotensin System / Q000502:physiology; D018570:Risk Assessment; D015398:Signal Transduction
D057911:Angiotensin Receptor Antagonists; D011945:Receptors, Angiotensin; D000804:Angiotensin II